Copyright
©The Author(s) 2022.
World J Hepatol. Mar 27, 2022; 14(3): 516-524
Published online Mar 27, 2022. doi: 10.4254/wjh.v14.i3.516
Published online Mar 27, 2022. doi: 10.4254/wjh.v14.i3.516
Case study | Status | Age | Sex | Country | Serum creatinine/eGFR | Renal manifestations | Treatment | Follow up | Outcomes |
Karki et al[30] | I.C | 48 yr | M | India | 8.1 mg/dL | ATN(Hemoglobin Cast) | Hemodialysis; Supportive care | 3 mo | Improved kidney function |
Verschuuren et al[13] | I.C | 34 yr | F | Netherlands | 10 mg/dL | ATN | Hemodialysis; Supportive care | 3 wk | Complete kidney function recovery |
Biliotti et al[51] | I.C | 57 yr | M | Italy | 44 mL/min | NR | Sofosbuvir; Ribavarin | 3 wk | Patient died from MRSA infection |
Guinault et al[33] | I.C | 48 yr | M | France | 3.6 mg/dL | MPGN | Steroids | 4 mo | |
Kamar et al[34] | K.T | 33 yr | M | France | 2.1 mg/dL | MPGN | Steroids | 16 mo | Improved kidney function |
Kamar et al[34] | K.T | 26 yr | M | France | 2.4 mg/dL | IgAN | Ribavarin 3 mo | 9 mo | Stable kidney function |
Kamar et al[34] | K.T | 40 yr | M | France | 2.1 mg/dL | IgAN | Change in IS + Rituximab | 3 mo | |
Kamar et al[34] | K.T | 24 yr | M | France | 2.3 mg/dL | MPGN | Rituximab | 3 yr | Renal replacement therapy |
Kamar et al[52] | K.T | 28 yr | M | France | 2.4 mg/dL | ATN | None | 3 mo | Serum creatinine returned to baseline |
Del Bello et al[32] | K.T | 46 yr | M | France | 2 mg/dL | MPGN | Ribavarin 30 mo | 12 mo | Improved serum creatinine |
- Citation: Kovvuru K, Carbajal N, Pakanati AR, Thongprayoon C, Hansrivijit P, Boonpheng B, Pattharanitima P, Nissaisorakarn V, Cheungpasitporn W, Kanduri SR. Renal manifestations of hepatitis E among immunocompetent and solid organ transplant recipients. World J Hepatol 2022; 14(3): 516-524
- URL: https://www.wjgnet.com/1948-5182/full/v14/i3/516.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i3.516